You have read all your free articles, to continue reading subscribe to read the rest of this content.
Oncorena has announced the Swedish Medical Products Agency’s approval of the Phase 1/2 of First in Patient trial of the compound orellanine in patients with metastatic renal cancer in dialysis. Preclinical evidence shows that orellanine, a well known fungus toxin, specifically exerts powerful aAlready a subscriber Login You have read…
LEO Pharma has announced that the first patients have been dosed in a phase 3 clinical study of tralokinumab. Tralokinumab is an investigational human monoclonal antibody that specifically targets the cytokine IL-13, which plays an important role in the development of moderate-to-severe atopic dAlready a subscriber Login You have read all…
RhoVac has received and validated results from its 3-year follow-up of the patients who took part in its phase I/II study that was concluded in 2018. The top-line results shows that the vast majority of patients still had undetectable PSA. Furthermore, the RhoC specific immune response has so farAlready a…
Swedish Orphan Biovitrum announces that the FDA has issued a Study may proceed letter for the first study in humans, thereby accepting the investigational new drug (IND) application for the drug candidate SOBI003. In addition, SOBI003 was granted Fast Track status by the FDA. SOBI003 is a cheAlready a subscriber Login You have read…
